Filing Flows › Health Care › DataMeds AI (MEDS)
DataMeds AI (MEDS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 17, 2026 · DataMeds AI (MEDS) Q2 2026 earnings results →
Q2 2026 Revenue down 77% year over year to $1.8M · operating margin -412.7%
DataMeds AI made $1.8M in Q2 2026 (-77% Y/Y): Pharmacy Retail Sales $1.6M, Third Party Logistics Services $123K, Product $67K. Operating margin -412.7%, net loss $18.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 17, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.8M in Q2 2026, down 77% year over year and up 14% from the previous quarter. Pharmacy Retail Sales was the largest line at 89% of revenue. Product lost $7.5M year over year (down 99%), 124% of the total change.
Gross margin was 10.2%, up 3.7 points from Q2 2025. Operating costs exceeded revenue by $7.3M, an operating margin of -412.7%. Operating expenses grew 25% against a revenue fall of 77%. The fastest-growing cost line was General & admin (+45%). The quarter ended with a net loss of $18.4M, wider than the previous quarter's $7.7M loss. Net interest and other expense of $11.0M was the main reason.
Operating cash flow was −$2.9M. Non-cash charges added back $357K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $13.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 17, 2026 | $1.8M | -77% | -412.7% | −$18.4M | −$2.9M |
| Q1 2026 | 10-Q | May 19, 2026 | $1.6M | -86% | -385.7% | −$7.7M | −$3.4M |
| Q4 2025 | 10-K | Mar 20, 2026 | $1.7M | -86% | n/m | −$27.9M | −$6.3M |
| Q3 2025 | 10-Q | Nov 19, 2025 | $3.0M | -47% | n/m | −$34.3M | −$1.1M |
| Q2 2025 | 10-Q | Aug 19, 2025 | $7.8M | 175× | -70.6% | −$6.7M | −$2.1M |
| Q1 2025 | 10-Q | May 12, 2025 | $10.9M | — | -288.6% | −$32.4M | −$1.3M |
| Q4 2024 | 10-K | Mar 25, 2025 | $12.4M | — | -30.2% | −$4.3M | −$2.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About DataMeds AI
DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.
In its own words, from its 8-K, filed Aug 18, 2026.
DataMeds AI against its Wholesale-Drugs, Proprietaries & Druggists' Sundries peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -77% against the peers' median +5%. Operating margin: -412.7% against the peers' median 1.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MEDS DataMeds AI | Q2 2026 | $1.8M | -77% | -412.7% |
| MCK McKesson | Q2 FY27 | $111.0B | +8% | 1.4% |
| COR Cencora | Q3 FY26 | $84.8B | +5% | 1.3% |
| CAH Cardinal Health | Q1 FY27 | $67.5B | +6% | 1.1% |
| HLF Herbalife | Q3 2026 | $1.4B | +6% | 10.3% |
| NUS Nu Skin Enterprises | Q3 2026 | $311M | -15% | 1.6% |
| COSM Cosmos Health | Q2 2026 | $19.0M | +29% | -15.4% |
| STEK Stemtech | Q2 2026 | $629K | -10% | -20.0% |
| ESYN HWH International | Q2 2026 | $64K | -79% | 328.1% |
Source: DataMeds AI 10-Q on SEC EDGAR · CIK 2030763 · Wholesale-Drugs, Proprietaries & Druggists' Sundries
13F: who owns MEDS and who is buying
More on MEDS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results